Cargando…
In vivo affinity and target engagement in skin and blood in a first‐time‐in‐human study of an anti‐oncostatin M monoclonal antibody
AIMS: The oncostatin M (OSM) pathway drives fibrosis, inflammation and vasculopathy, and is a potential therapeutic target for inflammatory and fibrotic diseases. The aim of this first‐time‐in‐human experimental medicine study was to assess the safety, tolerability, pharmacokinetics and target engag...
Autores principales: | Reid, Juliet, Zamuner, Stefano, Edwards, Ken, Rumley, Sally‐Anne, Nevin, Katherine, Feeney, Maria, Zecchin, Chiara, Fernando, Disala, Wisniacki, Nicolas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6138480/ https://www.ncbi.nlm.nih.gov/pubmed/29900565 http://dx.doi.org/10.1111/bcp.13669 |
Ejemplares similares
-
Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis
por: Denton, Christopher P, et al.
Publicado: (2022) -
The role of the oncostatin M/OSM receptor β axis in activating dermal microvascular endothelial cells in systemic sclerosis
por: Marden, G., et al.
Publicado: (2020) -
Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti- oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trials
por: Choy, Ernest H, et al.
Publicado: (2013) -
Oncostatin M Induction of Monocyte Chemoattractant Protein 1 is Inhibited by Anti-oncostatin M Receptor Beta Monoclonal Antibody KPL-716
por: RICHARDS, Carl D., et al.
Publicado: (2020) -
Oncostatin M is overexpressed in skin squamous-cell carcinoma and promotes tumor progression
por: Simonneau, Marie, et al.
Publicado: (2018)